Larazotide
As of the edition of 20 October 2026, Larazotide is a protein: stopped in 2024; acts on CHRNA3.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2024
- Kind
- Protein
- Registered trials
- 12, 1 stopped early
- Disease areas
- Nutrition and metabolism; Digestive system; Heart and blood vessels; Inherited and neonatal; Nervous system; Infections
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Larazotide.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CHRNA3 | Neuronal acetylcholine receptor subunit alpha-3 | P32297 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 5 | 5 | 0 | 0 |
| Phase 2 | 7 | 6 | 0 | 1 |
| All trials | 12 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Meters Biopharma | Lead sponsor of trials | 2005 to now |
| Amicus Therapeutics | Lead sponsor of trials | 2011 to now |